Cancer Research Institute
Clinical Trials
Shanghai Henlius Biotech, Inc. / “A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC)”
This study is currently enrolling.
The purpose of this study is to compare the efficacy of the investigational drug and placebo (an inactive substance) in combination with chemotherapy and concurrent radiotherapy in your disease and collect safety information on ...
StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention among Adolescent and Young Adult Childhood Cancer Survivors
This study is currently enrolling.
The overall goals of this study are: (1) To compare the effect of 2 different physical activity programs on physical activity levels in adolescents and young adults who received and completed treatment for cancer; and (2) To me ...
STML-ELA-022 A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer (ELEVATE)
This study is currently enrolling.
This research study is being done to find out if elacestrant is safe and tolerable when given in combination with one of the following study drugs, approved in the treatment of advanced breast cancer: alpelisib, everolimus, pal ...
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
This study is currently enrolling.
This study is being done to answer the following question: Is the combination of T-DM1 and a newer drug tucatinib, better than usual treatment with T-DM1 alone at preventing your cancer from returning? We are doing this study b ...
THE JANUS RECTAL CANCER TRIAL: A RANDOMIZED PHASE II TRIAL TESTING THE EFFICACY OF TRIPLET VERSUS DOUBLET CHEMOTHERAPY TO ACHIEVE CLINICAL COMPLETE RESPONSE IN
PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER
PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER
This study is currently enrolling.
To evaluate and compare the cCR rates in patients with locally advanced rectal cancer treated with neoadjuvant LCRT followed by neoadjuvant mFOLFIRINOX versus neoadjuvant LCRT followed by neoadjuvant mFOLFOX6.To evaluate and co ...
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
This study is currently enrolling.
We are doing this study to find better ways to diagnose, treat and prevent cancers in children, adolescents and young adults. To do this, we need to learn more about cancers that happen to children, adolescents and young adults ...
Umbrella Long-Term Follow-Up Protocol
This study is currently enrolling.
The overall goal of this study is to keep in contact with participants of COG clinical trials, so that up-to-date information will be available about these participants as they get older. This includes current name, contact, an ...
XL092-009 A Phase 1b/2 Dose-Finding And Expansion Study Evaluating The Safety And Efficacy Of Xl092 Combined With Either AB521 OR AB521 Plus Nivolumab In Subjects With Advanced Clear Cell Renal Cell Carcinoma Or Other Advanced Solid Tumors
This study is currently enrolling.
To determine the recommended doses (RDs) of zanzalintinib and AB521 when administered in combination (doublet) in subjects with advanced solid tumors, and in combination plus nivolumab (triplet) in subjects with advanced ccRCC ...
XL092-303: A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer (STELLAR-303)
This study is currently enrolling.
You are being asked to take part in a clinical research study called XL092-303 because you have already received standard treatment for your cancer and your cancer has worsened or become intolerant to standard treatment for you ...